The Robert Packard Center for ALS Research at Johns Hopkins
Homepage
 


December 20, 2005

Researchers Uncover New Toxic Mechanism in ALS

Exactly how ALS — Lou Gehrig’s disease — damages motor neurons is one of medical science’s lingering mysteries. At least six mishaps within cells appear to contribute to the death of the nerves that enable muscle movement, but nothing stands out as the key problem.

Packard investigator Jean-Pierre Julien
Packard investigator
Jean-Pierre Julien

Now new studies by a Canadian research team and Japanese collaborators, with support from the Packard Center for ALS Research at Johns Hopkins, strengthen earlier theories that whatever ultimately tips motor neurons onto their downhill path likely comes from outside the cells. The work describes a mechanism in which a warped, toxic molecule is secreted from cells into a motor neuron’s environment, where it harms the neuron.

The studies, which are described in this month’s issue of Nature Neuroscience, could focus therapy research on easier-to-access areas outside of cells.

Led by Packard scientist Jean-Pierre Julien of Quebec’s Laval University, the work is largely based on mouse models of ALS — animals engineered with a mutant human gene responsible for a familial form the disease. Mice carrying the mutant SOD1 gene develop ALS and die. Those with normal SOD1 are fine.

In earlier novel studies where only some mouse cells carried mutant SOD1 genes, Julien’s team showed, to their great surprise, that even though motor neurons may carry mutant genes, they apparently don’t die as long as neighboring cells’ SOD1 is normal. And, conversely, having neighbors with mutant SOD1 can trip motor neuron death even if the motor neurons themselves have the healthy version. Other Packard scientists has confirmed the unusual results that point to the importance of a motor neuron’s surroundings in developing disease—what they call the “bad neighborhood” theory.

In the new studies, Julien’s team found that misshapen, mutant SOD1 is preferentially “booted out” of nervous system cells — secreted by motor neurons and other neighboring cells — into cell surroundings. Once there, the researchers show, the mutant SOD1 is directly toxic to motor neurons it encounters. It can also rouse nearby immune cells, the microglia, which themselves release neuron-harming agents.

The team’s studies began with a fishing expedition of sorts, using a yeast two-hybrid approach, a modern technique that uses a cell protein as “bait” to see what other molecules associate with it. Mutant SOD1 was consistently linked with chromogranins — molecules closely tied to cell-secretion systems. In both nerve-cell cultures and in the spinal cords of the model mice, the team observed mutant SOD1 — but not normal SOD1 — paired with chromogranins, Further, the scientists found the pairings throughout a cell’s secretory machinery, a “packaging” system called the trans-Golgi network. The older the mice, the more paired molecules appeared. “We believe that chromogranins chaperone the mutant SOD1, helping it through a cell’s secretory pathways,” says Julien.

Last, the researchers discovered that chromogranin production, and, accordingly, mutant SOD1 secretion, is dramatically stepped up in cells adjacent to motor neurons, bathing them in the misshapen molecule. “In a motor neuron that’s under siege from events within,” Julien says, “having toxic molecules outside may be a last straw in the cell’s coping ability. All this,” he says, “becomes a part of ALS pathology that hasn’t been explored.”


The research was supported by the Robert Packard Center for ALS Research at Johns Hopkins, the ALS Association, the Canadian Institutes of Health Research, the ALS Society of Canada, the Japan Society for the Promotion of Science and Japan Foundation for Neuroscience and Mental Health.

Scientists participating in the study are Makoto Urushitani (the first author) of Laval University and Attila Sik, Takashi Sakurai, Nobuyuki Nukina and Ryosuke Takahashi of the RIKEN Brain Science Institute in Saitama, Japan.

>>link to the Nature Neuroscience article

>>more Recent News


Recent news from the Robert Packard Center for ALS Research:
In ALS, It’s Not the Number of Ailing Astrocytes That Counts - June 12, 2008
Leaky Blood Vessels Add To ALS Damage, Could Offer New Repair Site - June 10, 2008
William H. Adams Foundation Pumps New Energy, Funds into Search for ALS Cure - May 6, 2008
Tell-Tale Protein Clumping in ALS is Less Complex Than Expected - April 10, 2008

ALS Mouse Study Highlights Astrocytes' Strong Potential as Therapy Target - February 7, 2008

Exciting New Human ALS Trial: Lithium and Riluzole - February 7, 2008
ALS Treatment: A Matter of Cleaning House? - December 19, 2007

New Study Brings What Goes Wrong in Inherited ALS into Focus - September 18, 2007

New ALS Protein Could Be a Keystone - August 9, 2007
Muscles More Than Passive Victims in ALS, Study Suggests - June 29, 2007
Saer and O’Neill Named Packard Center Board Co-Chairs - June 28, 2007

Self-Attack? Self-Repair? First Real Look at Gene Activity in ALS Models Sparks Thirst for Answers - May 3, 2007

Model of Accelerated Familial ALS Sheds Light on Disease Process - April 6, 2007
Early News From First Large Search for Sporadic ALS Genes - February 20, 2007
Human Stem Cell Transplants Mature Into Neurons and Make Contacts in Rat Spinal Cord - February 14, 2007




Enter your e-mail address to
join the free ALS News Network!

Johns Hopkins Medicine